Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 16;48(4):172. doi: 10.3892/or.2022.8387

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Hu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — High CDCA5 expression across TCGA cancers and invasive breast cancer. (A) CDCA5 mRNA expression in various types of cancer compared with normal tissues from the UALCAN database. ***P<0.001. Expression of CDCA5 in BRCA based on (B) sample types, (C) individual cancer stages and (D) TP53 mutation status from TCGA samples. (E) Overall, (F) disease-free and (G) distant metastasis-free survival curves from the Kaplan-Meier Plotter, and the evaluation of the impact of the low (black line) and high (red line) CDCA5 expression. ****P<0.0001. CDCA5, cell division cycle-associated 5; TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectal adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma.